Sustainability | March 06, 2025
J. B. Chemicals & Pharmaceuticals announces DJSI score of 77
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
Metropolis Clinical Pathology will acquire and operate all laboratories and collection centers of Scientific Pathology in Agra and neighbouring towns through a slump sale transaction
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Subscribe To Our Newsletter & Stay Updated
